Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, Megan Othus, Mary-Elizabeth M. Percival, Paul C. Hendrie, Bart L. Scott, Jacob S. Appelbaum, Anna B. Halpern, Vivian G. Oehler, Johnnie J. Orozco, Sioban B. Keel, Janis L. Abkowitz, Jason P. Cooper, Ryan D. Cassaday, Kaysey F. Orlowski, Anise J. Marshall, Clarisa N. Brown, Elihu H. Estey, Roland B. Walter

Blood (2021) 138 (Supplement 1): 34.

https://doi.org/10.1182/blood-2021-151658

Published: 2021

Journal Articles

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Colin D. Godwin, MDMPhil, Megan Othus, PhD, Mary-Elizabeth M. Percival, MD, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Kelda M. Gardner, PA-C, Sioban B. Keel, MD, Tejaswini M. Dhawale, MD, Vivian G. Oehler, MD, Janis L. Abkowitz, MD, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Kaysey F. Orlowski, Alice Woo, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2019) 134 (Supplement_1): 3892.

https://doi.org/10.1182/blood-2019-126009

Published: 2019

Journal Articles

Randomized Study of CPX-351 for Medically Less-Fit Adults with Newly Diagnosed Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm

Roland B. Walter, MD PhD MS, Megan Othus, PhD, Kaysey F. Orlowski, Emily N. McDaniel, Bart L. Scott, MD, Pamela S. Becker, MD PhD, Mary-Elizabeth M. Percival, MD MS, Paul C. Hendrie, MD PhD, Bruno C Medeiros, MD, Michael T. Chiarella, Arthur C. Louie, Elihu H. Estey, MD

Blood (2017) 130 (Supplement 1): 1346.

https://doi.org/10.1182/blood.V130.Suppl_1.1346.1346

Published: 2017

Journal Articles

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study

Anna B. Halpern, MD, Sarah A. Buckley, MD, Megan Othus, PhD, Emily M Huebner, Kaysey F. Orlowski, Bart L Scott, MD, Andrea M. Perdue, PA-C, Heather A. Smith, PA-C, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Stephanie Cassone, MSN, FNP-BC, Tara L. Chen, PharmD, BCOP, Derek L. Stirewalt, Elihu H. Estey, MD, Roland B. Walter, MD PhD

Blood (2016) 128 (22): 1064.

https://doi.org/10.1182/blood.V128.22.1064.1064

Published: 2016

Journal Articles

A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Anna B. Halpern, MD, Megan Othus, PhD, Emily M Huebner, Kaysey F. Orlowski, Bart L. Scott, MD, Heather A. Smith, PA-C, Pamela S. Becker, MD PhD, Mary-Elizabeth M. Percival, MD, Paul C. Hendrie, MD PhD, Andrea M. Perdue, PA-C, Tara L. Chen, PharmD, BCOP, Sarah A. Buckley, MD, Harry P. Erba, MD PhD, Elihu H. Estey, MD, Roland B. Walter, MD PhD

Blood (2016) 128 (22): 1068.

https://doi.org/10.1182/blood.V128.22.1068.1068

Published: 2016

Journal Articles

Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Asma Anwar, MD, Anna B. Halpern, MD, Megan Othus, PhD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Pamela S. Becker, MD PhD, Andrea M. Perdue, PA-C, Heather A. Smith, PA-C, Tara L. Chen, PharmD, Sarah A. Buckley, MD, Kaysey F. Orlowski, Morgan A. Powell, BS, Elihu H. Estey, MD, Roland B. Walter, MD PhD MS

Blood (2015) 126 (23): 1339.

https://doi.org/10.1182/blood.V126.23.1339.1339

Published: 2015

Journal Articles

Minimal Residual Disease (MRD) As Exploratory Endpoint in a Phase 1 Study of the Anti-CD123 Mab CSL362 Given As Post-Remission Therapy in Adult Acute Myeloid Leukemia (AML)

B. Douglas Smith, MD, Andrew W. Roberts, MBBS, PhD, Gail J. Roboz, MD, Mark DeWitte, VMD, Anna Ferguson, BSN, RN, Linda Garrett, RN, Tania Curcio, Kaysey F. Orlowski, Sue Dasen, MS, Debra M. Bensen-Kennedy, MD, Roland B. Walter, MD PhD MS

Blood (2015) 126 (23): 3819.

https://doi.org/10.1182/blood.V126.23.3819.3819

Published: 2015

Journal Articles

Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment-Related Mortality

Roland B. Walter, MD PhD MS, Kaysey F. Orlowski, Morgan A. Powell, BS, Pamela S. Becker, MD PhD, Paul C. Hendrie, MD PhD, Fabiana Ostronoff, MD, Elizabeth M. Ranker, PA-C, Megan Othus, PhD, Arthur C. Louie, MD, Elihu H. Estey, MD

Blood (2014) 124 (21): 994.

https://doi.org/10.1182/blood.V124.21.994.994

Published: 2014

Journal Articles

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study

Anna B. Halpern, MD, Elihu H. Estey, MD, Megan Othus, PhD, Kaysey F. Orlowski, Morgan A. Powell, BS, Tara L. Chen, PharmD, Pamela S. Becker, MD PhD, Bart L. Scott, MD, Paul C. Hendrie, MD PhD, Fabiana Ostronoff, MD, Elizabeth M. Ranker, PA-C, Mazyar Shadman, MD MPH, Derek L. Stirewalt, MD, Roland B. Walter, MD PhD MS

Blood (2014) 124 (21): 3730.

https://doi.org/10.1182/blood.V124.21.3730.3730

Published: 2014

Journal Articles

First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse

B. Douglas Smith, MD, Gail J. Roboz, MD, Roland B. Walter, MD PhD, Jessica K. Altman, MD, Anna Ferguson, BSN, RN, Tania J. Curcio, R.N, Kaysey F. Orlowski, Linda Garrett, RN, Samantha J Busfield, PhD, Megan Barnden, PhD, Brad Sedgmen, PhD, Souravi Ghosh, PhD, Sarah Hosback, PhD, Roslyn Davis, MSc, Allison Dyson, BSc, Sue Dasen, MS, Mark DeWitte, VMD, Debra M. Bensen-Kennedy, MD, Andrew W. Roberts, MBBS, PhD

Blood (2014) 124 (21): 120.

https://doi.org/10.1182/blood.V124.21.120.120

Published: 2014

Journal Articles

Gemtuzumab Ozogamicin In Combination With Vorinostat and Azacitidine In Older Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML): Final Results From A Phase 1/2 Study

Roland B. Walter, MD, PhD, Bruno C. Medeiros, MD, Kelda M. Gardner, PA-C, Kaysey F. Orlowski, Leonel Gallegos, MD, Bart L Scott, MD, Paul C. Hendrie, MD, PhD, Elihu H. Estey, MD

Blood (2013) 122 (21): 3936.

https://doi.org/10.1182/blood.V122.21.3936.3936

Published: 2013

NARROW

A Phase 1/2 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Phase 1 Trial of Cladribine, High-Dose Cytarabine, G-CSF, and Dose-Escalated Mitoxantrone (CLAG-M) Plus Gemtuzumab Ozogamicin in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm

Randomized Study of CPX-351 for Medically Less-Fit Adults with Newly Diagnosed Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): Final Results from a Phase 1/2 Study

A Phase 1/2 Study of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Phase 1 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

Minimal Residual Disease (MRD) As Exploratory Endpoint in a Phase 1 Study of the Anti-CD123 Mab CSL362 Given As Post-Remission Therapy in Adult Acute Myeloid Leukemia (AML)

Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment-Related Mortality

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS): A Phase 1 Study

First-in Man, Phase 1 Study of CSL362 (Anti-IL3Rα / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse

Gemtuzumab Ozogamicin In Combination With Vorinostat and Azacitidine In Older Patients With Relapsed Or Refractory Acute Myeloid Leukemia (AML): Final Results From A Phase 1/2 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only